TABLE 2.
i.n./i.m. vaccine regimen increases both linear epitope magnitude and breadth of systemic gp120-specific IgG responses
| HIV Env epitope (peptide range, aa) | Signal intensitya for the indicated monkey and time point |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A6E030 |
A6E042 |
AU71S |
A6E088 |
|||||||||
| Prime | i.n.1 | i.n.2 | i.n./i.m.3 | Prime | i.n.1 | i.n.2 | i.n./i.m.3 | i.n.2 | i.n./i.m. 3 | i.n.2 | i.n./i.m.3 | |
| C1.1 (28–29) | 1 | 94 | 2,369 | 13,162 | 1 | 1 | 1 | 1 | 50 | 46 | 264 | 1,472 |
| C1.2 (32–36) | 1 | 10 | 2,128 | 7,091 | 1 | 1 | 3,646 | 22,843 | 37 | 21 | 4,558 | 20,443 |
| C2.1 (83–84) | 1 | 42 | 1,115 | 4,050 | 1 | 1 | 62 | 347 | 17 | 4 | 43 | 39 |
| C2.2 (91) | 1 | 6,599 | 7 | 31,884 | 1 | 501 | 18,187 | 18,831 | 15 | 205 | 43 | 7,344 |
| V3 (93–106) | 6,115 | 41,303 | 50,112 | 65,186 | 4,321 | 60,998 | 57,211 | 60,520 | 18,498 | 22,535 | 54,913 | 57,958 |
| V4 (126–127) | 168 | 207 | 11,719 | 9,690 | 1 | 1 | 1 | 1 | 162 | 102 | 471 | 649 |
| C4 (136–139) | 1,671 | 2,361 | 31,085 | 47,253 | 1 | 232 | 1 | 113 | 7,846 | 7,153 | 562 | 313 |
| V5 = C5 (147–151) | 1 | 472 | 3,155 | 8,040 | 1 | 1 | 721 | 293 | 106 | 29 | 9,176 | 13,172 |
| C5.1 (156–159) | 1 | 6,594 | 24,739 | 23,126 | 1 | 115 | 504 | 1,610 | 68 | 164 | 6,153 | 10,711 |
| gp41 ID (187–196) | 96 | 781 | 524 | 1,495 | 1 | 56 | 1 | 512 | 597 | 518 | 117 | 114 |
| MPER (212–216) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 111 | 56 | 8 | 4 |
a
Maximum binding (signal intensity) to a single peptide within each identified epitope. Italic, signal intensity of 1,000 to 10,000; bold italic, signal intensity of 10,000 to 30,000; underlined bold italic, signal intensity of >30,000. Plasma samples for the postprime and post-i.n. boost 1 time points were not available for animals AU71S and A6E088 due to sample limitation.